Kingsview Wealth Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $98.5M | Buy |
82,083
+6,612
| +9% | +$6.76M | 1.19% | 13 |
|
|
2026
Q1 | $69.4M | Buy |
75,471
+4,868
| +7% | +$4.94M | 0.95% | 17 |
|
|
2025
Q4 | $75.9M | Sell |
70,603
-12,792
| -15% | -$12.2M | 1.09% | 15 |
|
|
2025
Q3 | $63.6M | Buy |
83,395
+11,111
| +15% | +$8.27M | 0.97% | 18 |
|
|
2025
Q2 | $56.3M | Buy |
72,284
+2,839
| +4% | +$2.21M | 0.95% | 20 |
|
|
2025
Q1 | $57.4M | Buy |
69,445
+5,600
| +9% | +$4.66M | 1.08% | 15 |
|
|
2024
Q4 | $49.3M | Buy |
63,845
+9,166
| +17% | +$7.59M | 0.96% | 21 |
|
|
2024
Q3 | $48.4M | Buy |
54,679
+1,849
| +3% | +$1.66M | 1.02% | 17 |
|
|
2024
Q2 | $47.8M | Buy |
52,830
+2,199
| +4% | +$1.76M | 1.13% | 13 |
|
|
2024
Q1 | $39.4M | Buy |
50,631
+1,421
| +3% | +$1.01M | 0.99% | 17 |
|
|
2023
Q4 | $28.7M | Buy |
49,210
+6,895
| +16% | +$4.02M | 0.86% | 18 |
|
|
2023
Q3 | $22.7M | Sell |
42,315
-3,110
| -7% | -$1.6M | 0.82% | 18 |
|
|
2023
Q2 | $21.3M | Sell |
45,425
-777
| -2% | -$326K | 0.84% | 18 |
|
|
2023
Q1 | $15.9M | Buy |
46,202
+4,309
| +10% | +$1.45M | 0.67% | 24 |
|
|
2022
Q4 | $15.3M | Buy |
41,893
+15,671
| +60% | +$5.56M | 0.67% | 27 |
|
|
2022
Q3 | $8.48M | Buy |
26,222
+1,558
| +6% | +$494K | 0.4% | 57 |
|
|
2022
Q2 | $8M | Sell |
24,664
-27,294
| -53% | -$8.19M | 0.38% | 60 |
|
|
2022
Q1 | $14.9M | Buy |
51,958
+37,928
| +270% | +$9.76M | 0.66% | 23 |
|
|
2021
Q4 | $3.88M | Buy |
14,030
+597
| +4% | +$151K | 0.16% | 140 |
|
|
2021
Q3 | $3.1M | Sell |
13,433
-8,361
| -38% | -$2.06M | 0.15% | 156 |
|
|
2021
Q2 | $5.04M | Buy |
21,794
+3,543
| +19% | +$712K | 0.25% | 85 |
|
|
2021
Q1 | $3.38M | Buy |
18,251
+7,044
| +63% | +$1.38M | 0.19% | 121 |
|
|
2020
Q4 | $1.89M | Buy |
11,207
+5,766
| +106% | +$861K | 0.14% | 165 |
|
|
2020
Q3 | $805K | Buy |
5,441
+1,098
| +25% | +$170K | 0.07% | 267 |
|
|
2020
Q2 | $713K | Sell |
4,343
-1,039
| -19% | -$159K | 0.07% | 261 |
|
|
2020
Q1 | $747K | Buy |
5,382
+2,504
| +87% | +$344K | 0.1% | 215 |
|
|
2019
Q4 | $378K | Sell |
2,878
-719
| -20% | -$83.3K | 0.05% | 334 |
|
|
2019
Q3 | $402K | Sell |
3,597
-466
| -11% | -$51.9K | 0.06% | 291 |
|
|
2019
Q2 | $450K | Sell |
4,063
-432
| -10% | -$50.9K | 0.08% | 259 |
|
|
2019
Q1 | $583K | Buy |
4,495
+2,602
| +137% | +$316K | 0.09% | 240 |
|
|
2018
Q4 | $219K | Sell |
1,893
-54
| -3% | -$6.03K | 0.05% | 329 |
|
|
2018
Q3 | $209K | Buy |
+1,947
| New | +$195K | 0.04% | 335 |
|
Other funds holding LLY
Kingsview Wealth Management's LLY Position: Q2 2026 in Review
Kingsview Wealth Management increased its Eli Lilly (LLY) stake by 8.8% in Q2 2026, buying an estimated $6.76M and bringing the position to 82,083 shares worth $98.5M. The position accounts for 1.19% of the portfolio, ranked #13.
Kingsview Wealth Management first reported a position in LLY in Q3 2018 and has held it in 32 quarters since. 4,598 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Kingsview Wealth Management held 82,083 shares of Eli Lilly worth $98.5M as of Q2 2026.
- Kingsview Wealth Management bought 6,612 Eli Lilly shares in Q2 2026, an estimated $6.76M.
- Eli Lilly made up 1.19% of Kingsview Wealth Management's portfolio in Q2 2026, its #13 holding.
- Kingsview Wealth Management first reported a position in Eli Lilly in Q3 2018 and has held it in 32 quarters since.
- 4,598 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.